Zacks Investment Research upgraded shares of Intec Pharma Ltd (NASDAQ:NTEC) from a hold rating to a buy rating in a research note released on Friday. The firm currently has $5.50 price objective on the stock.
According to Zacks, “Intec Pharma Ltd. is a biopharmaceutical company. The company focused on developing drugs through proprietary Accordion Pill platform technology. Its product candidates in clinical trial stages consists of Accordion Pill Carbidopa/Levodopa developed for the indication of treatment of Parkinson’s disease symptoms; Accordion Pill Zaleplon is being developed for the indication of treatment of insomnia, including sleep induction and the improvement of sleep maintenance. Intec Pharma Ltd. is based in JERUSALEM, Israel. “
Separately, Maxim Group restated a buy rating and issued a $9.00 price target on shares of Intec Pharma in a research note on Friday.
Shares of Intec Pharma (NASDAQ:NTEC) traded down 1.96% on Friday, reaching $5.00. 120 shares of the company traded hands. The firm’s 50 day moving average is $4.83 and its 200 day moving average is $5.22. The company’s market capitalization is $57.00 million. Intec Pharma has a one year low of $3.03 and a one year high of $6.36.
About Intec Pharma
Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intec Pharma Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma Ltd and related companies with MarketBeat.com's FREE daily email newsletter.